TABLE 3.
Expression of theacy-1 cDNA in either the muscle or the nervous system partially rescues the larval arrest ofacy-1 null mutants
| Genotype | Tissue specificity of transgene |
Dosagea | Fraction reaching adulthoodb |
% reaching adulthood |
No. of days monitored |
|---|---|---|---|---|---|
| acy-1(pk1279) | No transgene | NA | 0/24 | 0 | 25 |
| acy-1(pk1279); ceEx108 [myo-3::acy-1(+)] | Muscle | Low | 20/37 | 54 | 5 |
| acy-1(pk1279); ceEx67 [myo-3::acy-1(+)] | Muscle | High | 47/101 | 47 | 5 |
| acy-1(pk1279); ceEx87 [myo-3::acy-1(gf)] | Muscle | High | 55/82 | 67 | 5 |
| acy-1(pk1279); ceEx97 [rab-3::acy-1(+)] | Nervous system | High | 11/33 | 33 | 5 |
| acy-1(pk1279); ceEx98 [rab-3::acy-1(gf)] | Nervous system | High | 6/64 | 9.4 | 7 |
a
Low dosage represents an injection concentration of 5 ng/μl; high dosage represents 15 ng/μl for myo-3-driven expression, 50 ng/μl for rab-3-driven expression of the wild-type acy-1 cDNA, and 15 ng/μl for rab-3-driven expression of the gain-of-function acy-1 cDNA.
b
This is the fraction of animals with uniform expression of the cotransformation GFP marker (either myo-3::GFP or rab-3::GFP, depending on the experiment) that reach adulthood. Denominator equals sample size.